Vanda Pharmaceuticals (VNDA) Total Current Liabilities (2010 - 2026)

Vanda Pharmaceuticals has disclosed Total Current Liabilities across 17 years of filings, most recently posting $135.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $135.6 million, up 30.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.6 million (up 30.46% YoY), and the FY2025 annual result was $145.2 million, up 45.19% from the prior year.
• Total Current Liabilities came in at $135.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $145.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $145.2 million in Q4 2025 to a low of $84.8 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $93.3 million (2024), against an average of $101.0 million.
• Across the five-year window, Total Current Liabilities jumped 46.87% in 2022 and slipped 8.41% in 2023, its largest moves.
• Vanda Pharmaceuticals' Total Current Liabilities stood at $91.4 million in 2022, then decreased by 4.09% to $87.7 million in 2023, then increased by 14.01% to $100.0 million in 2024, then soared by 45.19% to $145.2 million in 2025, then declined by 6.6% to $135.6 million in 2026.
• The last three Total Current Liabilities figures came in at $135.6 million (Q1 2026), $145.2 million (Q4 2025), and $117.9 million (Q3 2025), per Business Quant data.